Technology
Emerging Growth Technologies
(CTUM-OTC)

Consortium Service Management Group, Inc.

500 North Shoreline #701 North
Corpus Christi, TX 78471
Phone: 361-887-7546



Donald S. Robbins
President and
Chief Executive Officer

Interview conducted by:
Lynn Fosse
Senior Editor

CEOCFOinterviews.com
August 2003

BIO:
Mr. Donald S. Robbins, President and CEO

Mr. Donald S. Robbins is a founder of CSMG, and currently serves as President, Chief Executive Officer and Board Member.  Mr. Robbins has been instrumental in developing relationships with the company’s foreign and domestic partners and oversees the management of the company, as well as any new technology acquisitions, evaluation and investment.  These acquisitions have included state of the art technologies, such as Live Soft Biological Tissue Bonding for humans and animals and CO₂ separation technologies for landfill gas and anaerobic animal waste processing.

Prior to founding CSMG, Mr. Robbins gained extensive experience in the financial services and insurance industries, where he held numerous licenses such as Registered Investment Advisor and Registered Principal.  He was nationally recognized in the financial services industry and has lectured in public seminars as well as industry related symposiums.  During his 22 years in the financial services industry, Mr. Robbins has received over 140 awards and honors including numerous “Man of the Year” awards from multinational financial service and insurance companies.

Mr. Robbins is also President and CEO of Live Tissue Connect, Inc. and Chairman and CEO of Anaerobic Animal Waste, Inc.

Mr. Robbins is on the Supervisory Council of United Engineering Company and serves as a foreign member of the International Association of Welding of the E. O. Paton Institute of Electric Welding National Academy of Sciences of Ukraine.

Company Profile:
 
Consortium Service Management Group, Inc. (CTUM-OTC) has invested heavily and formed strong relationships in a portfolio of state of the art technologies suitable for US and international niche markets. CSMG has been instrumental in working with Ukraine Scientific, Space, Electronics, Defense, Agriculture, Medical Institutes and Research Clinics in identifying advanced technologies and financing the completion of research and development (R & D) of these technologies. Through these activities CSMG has secured ownership and exclusive world rights for several cutting edge technologies including medical devices, environment related and other high tech niche market products. Their exclusive rights include patents, licensing, manufacture, marketing and distribution. In 2000 CSMG began introducing these products to the US and International markets.

CSMG’s corporate objectives are first focused on three areas in the near future for continued development, manufacture and marketing of their current portfolio of technologies including Live Biological Tissue Bonding Platform Technology, CO-2 Separator for landfill gas and Anaerobic Animal Waste Processing Plants. Second, CSMG will continue to evaluate and enlarge its sphere of portfolio products and take in a number of new technologies in the welding, oil and gas and medical areas such as their expandable containers.

Third, CSMG plans continued growth of the United Engineering Joint Stock Company.
UEC was founded in 1993 between CSMG as the Foreign Investor and largest shareholder and by the State Property Fund of Ukraine along with 14 of Ukraine's largest Defense Contractors and Enterprises. UEC is working in the area of ICBM dismantlement under the START Treaties and defense conversion projects. UEC has played a key role in the development and engineering design of the Anaerobic Animal Waste Technology owed by CSMG.

CEOCFOinterviews: Mr. Robbins, please give us a brief history of Consortium Service Management Group.

Mr. Robbins: “Consortium Service Management Group was founded in November of 1992. We started the company to take advantage of some of the opportunities that were in the former Soviet Union. Since 1994, we have become the largest shareholder and foreign investor in an engineering company in the Ukraine called the United Engineering Company JSC with Foreign Investment. We have been involved in the dismantlement of weapons of mass destruction, under the START Treaty since about 1995 and now have now begun conversion into the public sector of the engineering industry. During that time, we developed very good relationships with The Academy of Sciences and some of the largest contractors and companies in the Ukraine. We began developing the company as we are now, which is a technology management company. We own, invest in, develop, finance R&D, patent, and bring new technologies to market.”

CEOCFOinterviews: What types of technologies do you look for?

Mr. Robbins: “We look for niche market technologies, which we think will have a strong impact in the market place and are highly competitive. Those technologies do not have to be in any specific field. Currently we have a couple of technologies that we are very happy with, one is the Live Biological Tissue Bonding technology, and another is the CO-2 separation technology for separating CO-2 from raw landfill gas.”

CEOCFOinterviews: Is all your research done in the Ukraine?

Mr. Robbins: “The Academy of Sciences of Ukraine has some of the top scientists in the world and we have developed a good relationship with both the scientists and with The Academy of Sciences. They have brought numerous projects for us to review.  We do not select them all because we could not afford to; we try to pick some of the better ones.”

CEOCFOinterviews: You had a release recently about a neurological breakthrough in biological tissue bonding; will you tell us more about it?

Mr. Robbins: “We have been developing biological tissue bonding technology since 1996 and the Ukrainians have been working with it before that. What it does is reconnect human tissue without the use of staples, glues, sealants, or sutures. One is able to have surgery on certain organs of the body where the organs are be reconnected without having   foreign matter left in the body. This is done using a smokeless radio frequency welding device. Unlike the other radio frequency bonding and welding technologies, our people have learned how to control the heat so there is no necrosis or charring of the tissue. This allows the tissue once it is reconnected to heal quickly and quicker than conventional methods.”

CEOCFOinterviews: Where are you going with it from here?

Mr. Robbins: “We own the technology and patents and have spent a number of years developing the various surgical procedures. We formed a company called Live Tissue Connect Inc. (LTC), which now holds the technology and are in the process of finding a medical industry CEO to head that company.  From that point on, Live Tissue Connect Inc. will take over the tissue bonding technology and we will take the technology into the world market and start regulatory processes in various countries. Depending on which country you are in and what type of procedure you go through, this could be a process of a few months or 2 to 3 years. We are already approved in the Ukraine for manufacturing and distribution. In some countries, it will take longer than other countries.”

CEOCFOinterviews: Does developing the technologies in the Ukraine make a difference when you are going out to the world with them?

Mr. Robbins: “I think that most of the technologies stand on their own. The Ukraine is recognized worldwide, especially with the E. O. Paton Institute of Electric Welding, National Academy of Sciences, Ukraine which is where this all started. The institute is recognized by governments around the world as being one of the premiere welding institutes of the world and they are highly respected.”

CEOCFOinterviews: Will you tell us about the CO-2 separator?

Mr. Robbins: “The CO-2 separator was designed for our company specifically for removal of CO-2 from raw landfill gas through the Academy of Sciences. It was specifically designed to solve the problem of landfill gas, so instead of landfill gas being captured and flared, we would be able to clean up the gas to what is called a high BTU gas and sell the gas into the pipeline as commercial product. We have had a couple of years of development on this product and have installed the first unit in Chastang, Alabama, which is just outside Mobile, Alabama, and we should be starting over here very shortly. “

CEOCFOinterviews: How many projects do you handle at any given time?

Mr. Robbins: “Overall, we try not to be involved in too many projects because they are all capital intensive. The idea is that we work with some major technologies that have a good commercial upside and bring them to market.  This is the first year that we are in that position. We worked with the Anaerobic Animal Waste Processing System, which solves the problems of the lagoons and large animal farms. We are not taking new projects on until we finish up with our tissue bonding and our CO-2 separator.”

CEOCFOinterviews: How have you been funding your projects, and how will you continue to fund?

Mr. Robbins: “We funded most of these projects internally but that will change for the commercialization. We will go out into the market place and raise capital, either through private placements, IPO’s or something of that nature. We have been very fortunate that we have had investors that have worked with us for a number of years and who have helped us fund these projects internally.”

CEOCFOinterviews: What would you like to say to potential investors and what should they know that perhaps they don’t realize when they look on the surface?

Mr. Robbins: “The tissue bonding technology has been referred to as the Holy Grail of the surgery industry. Who knows how long it will take to get it into the mainstream marketplace of the western world. Today we have done over a thousand successful human surgeries and we are currently running at the rate of 80 to 100 new surgeries per month. We are constantly expanding into different types of procedures for different types of organs. Tissue bonding technology was developed to restore the normal function of the organ and the surgeons tell us that they are able to reduce the amount of surgery time. The healing is, in their opinion, faster and there is very little scar tissue that you can see with the naked eye. In most instances where it is used, we get a leak-proof bond so there is no leakage. We have been able to sever and reconnect fallopian tubes for women who have had tubal ligation or tumors, and some of these women have had children after the tubes were reconnected. It is a fantastic technology and sooner or later it will blossom out.”

CEOCFOinterviews: Are there competing technologies in that area that are being worked on?

Mr. Robbins: “As far as we know there are other technologies that are using glues or sealants but we do not know how successful they are. There are a number of companies who have attempted to control the heating of the tissue by using some water or a composite plastic medium. The unique thing about our technology is that we do not need a medium to control the heat going on the tissue.”

CEOCFOinterviews: What does it take to get the products out there?

Mr. Robbins: “The first thing we have to do is hire a team in the medical area that is highly qualified. That team has to work with the various regulatory agencies of the various countries around the world to get approval for those projects and procedures and this must be done before you can take it into the market place and start distributing to hospitals and clinics.”

CEOCFOinterviews: In closing, what should people remember most about the company and the outlook for the future?

Mr. Robbins: “I think the thing that should be remembered most about the company is that we are a technology management company, which focuses on technologies that have a niche market. Those technologies are in a market that is needed and the technologies based on the internal work that we do, have a strong upside in the market place. That is our whole business.”

disclaimers

© CEOCFOinterviews.com – Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.